Zyversa Therapeutics Inc (ZVSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 303 | 102 | 528 | 72 | 1,612 |
| Other current assets | 0 | 15 | 169 | 98 | 0 |
| TOTAL | $742 | $464 | $996 | $549 | $2,110 |
| Non-Current Assets | |||||
| Intangibles | 0 | 0 | 0 | 18,648 | 18,648 |
| Other Non-Current Assets | 0 | 0 | 45 | 444 | 227 |
| TOTAL | $N/A | $N/A | $45 | $19,092 | $18,875 |
| Total Assets | $742 | $464 | $1,040 | $19,641 | $20,986 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 10,235 | 10,123 | 9,805 | 9,774 | 9,605 |
| Accrued Expenses | 3,303 | 2,727 | 2,961 | 2,915 | 2,399 |
| Other current liabilities | 128 | N/A | N/A | N/A | N/A |
| TOTAL | $14,867 | $12,850 | $12,766 | $12,690 | $12,004 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $852 | $852 |
| Total Liabilities | $14,867 | $12,850 | $12,766 | $13,541 | $12,855 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 8,096 | 8,096 | 8,096 | 8,096 | 4,773 |
| Common Shares | 1 | 1 | 1 | 1 | 0 |
| Retained earnings | -139,378 | -137,585 | -136,906 | -117,101 | -114,890 |
| Other shareholders' equity | -7 | -7 | -7 | -7 | -7 |
| TOTAL | $-14,124 | $-12,387 | $-11,726 | $6,100 | $8,130 |
| Total Liabilities And Equity | $742 | $463 | $1,040 | $19,641 | $20,986 |